Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Highlights from the Q2 2010 review of pharmaceutical and biotechnology dealmaking: Biopharma companies raised a total of $3.4bn through 96 financings. Twenty-one acquisitions together reached $20.2bn, thanks to five deals each exceeding $3 billion - in aggregate accounting for 91% of the M&A total. The alliance volume was up to 115 transactions for a total of $2.8 billion in pre-commercialization money, with seven deals surpassing the $100 million mark.
You may also be interested in...
The hedge fund operator offers $154 million after Cypress' unpopular licensing of an anti-psychotic drug. But Ramius might want to share the upside on the drug after all.
Celgene is acquiring Abraxane developer Abraxis Biosciences and planning an aggressive development and marketing push for the novel nanoparticle formulation of paclitaxel, with the aim of driving the drug's sales to $1 billion by 2015
In a bid to protect its most valuable product, Lantus, Sanofi’s new diabetes division intends to provide holistic solutions in an effort to help patients better manage their disease. Will it work?